Forecast

The analysts' average price target is €11.19 (-31.64%). The median is €8.61 (-47.40%).

Buy	0
Hold	5
Sell	1

News Go to news feed

ARCHIMED completes acquisition of ZimVie at $19.00 per share

ARCHIMED has completed the acquisition of dental implant maker ZimVie at $19.00 per share, valuing the company at about $536 million. ZimVie’s NASDAQ listing was terminated; the stock had returned 102% in the six months prior to the transaction. ZimVie generates annual revenues of $443 million, has a gross margin of 65.3%, and shows solid liquidity with a current ratio of 2.37. » More on de.investing.com
ZimVie expands through distribution partnership with Osstem Implant and merger agreement with ARCHIMED

ZimVie has entered into an exclusive distribution partnership with Osstem Implant for the Chinese market to sell its dental implants there. In addition, a merger agreement with investment firm ARCHIMED worth around 730 million US dollars has been announced, which includes a cash premium for shareholders. Analysts responded differently to the acquisition, while ZimVie reported mixed business results for the first quarter. » More on de.investing.com
ZimVie to be taken private after $730 million acquisition by ARCHIMED

ZimVie's shares jumped 122% after it was announced that the dental implant company will be acquired by investment firm ARCHIMED for approximately $730 million. Shareholders will receive $19 per share, representing a 99% premium over the 90-day average price. Once the transaction is completed, ZimVie will become a privately held company and its shares will no longer be traded on NASDAQ. » More on de.investing.com

Financials

In the last quarter, ZimVie Aktie had revenue of €98.98M and net profit of -€3.35M

(EUR)	June 2025	YoY
Revenue	98.98M	-
Gross profit	63.89M	-
Net profit	-3.35M	-
EBITDA	10.8M	-

Fundamentals

Metric	Value
Market capitalization	€461.26M
Number of shares	28.21M
52-week high/low	€16.37 - €7.02
Dividends	No
Beta	2.06
P/E ratio	-99.95
PEG ratio	-0.68
P/B ratio	1.29
P/S ratio	2.34

Company profile

ZimVie Inc., ein Medizintechnikunternehmen, entwickelt, produziert und vertreibt ein Portfolio von Produkten und Lösungen zur Behandlung einer Reihe von Wirbelsäulenpathologien und zur Unterstützung von Zahnersatz- und Restaurationsverfahren weltweit. Das Unternehmen bietet Zahnimplantatsysteme, Prothetik- und Abutmentprodukte, chirurgische Instrumente und Kits, Knochentransplantate, Barrieremembranen, Allografts und Kollagen-Wundversorgungsprodukte, Intraoralscanner, virtuelle Behandlungsplanungsdienste, Lösungen für die schablonengeführte Chirurgie, CAD/CAM-Workflowsysteme und patientenspezifische Restaurationskomponenten und Intraoralscanner sowie Wirbelsäulenfusionsimplantate und Instrumente für verschiedene Wirbelsäulenverfahren, Biologika und Knochenheilungstechnologien. Das Unternehmen bietet auch MIS-Lösungen wie Vital MIS und Timberline sowie Lösungen zur Bewegungserhaltung wie Mobi-C und The Tether an. ZimVie Inc. wurde im Jahr 2021 gegründet und hat seinen Hauptsitz in Westminster, Colorado.

Name	ZimVie Aktie
CEO	Vafa Jamali
Headquarters	Palm Beach Gardens, co USA
Website	zimvie.com
Sector	Health Care
Industry	Health Care Equipment & Supplies
IPO	08/23/2017
Employees	1,770